The Effects of Cardiopulmonary Bypass on Fibrin Formation and Lysis: Is a Normal Fibrinolytic Response Essential?
- 1 January 1996
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 27, 63-68
- https://doi.org/10.1097/00005344-199600001-00013
Abstract
Fibrinolytic activity in blood is regulated by a dynamic process that includes control of production, secretion, inhibition, and clearance of fibrinolytic proteins. The concentration of active tissue plasminogen activator (tPA) in the region of the thrombus controls the rate of fibrinolytic activation. We have developed a first-generation kinetic model that can be used to simulate the effects of secretion, inhibition, and clearance reactions on the concentrations of active tPA, active plasminogen activator inhibitor type 1 (PAI-1), and tPA/PAI-1 complex in the circulation. This model was used to estimate the rate and pattern of secretion of tPA and PAI-1 in individual subjects. We also undertook a laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction. Elevated PAI-1 activity in the absence of elevations in other acute-phase proteins suggested an intrinsic increase in PAI-1 secretion in patients post-myocardial infarction. Cardiopulmonary bypass (CPB) results in a major increase in fibrinolytic activity that has been associated with an increased risk for hemorrhage. Fibrinolytic proteins were sampled from patients both during surgery and for 2 days postoperatively. Total tPA antigen rose throughout CPB and returned to baseline in the post-operative period. PAI-1 activity fell during the initial bypass and by the end of bypass had returned to baseline. On the first to second postoperative day there was a large increase in PAI-1 activity and a significant decrease in tPA activity. These data suggest that during this period there is a window of risk for a thromboembolic event. There was, however, a large individual variability in patient response to CPB.Keywords
This publication has 24 references indexed in Scilit:
- Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina PectorisNew England Journal of Medicine, 1995
- Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Endogenous tissue-type plasminogen activator and risk of myocardial infarctionThe Lancet, 1993
- Regulation of the Acute Release of Tissue‐type Plasminogen Activator from the Endothelium by Coagulation Activation ProductsAnnals of the New York Academy of Sciences, 1992
- Release of vasoactive substances during cardiopulmonary bypassThe Annals of Thoracic Surgery, 1992
- A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolismArchives of internal medicine (1960), 1991
- Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- Effects of Aprotinin on Hemostatic Mechanisms during Cardiopulmonary BypassThe Annals of Thoracic Surgery, 1987
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987